Biogen Inc. (BIIB)

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.

BIIB shares have rallied the broader market over the past year, surged 47.2% compared to the S&P 500 Index ($SPX) 23.3% surge. Moreover, in 2026, the stock has grown nearly 8.3%, outperforming the SPX’s 7.4% rise as well. NVDA Earnings Bull Put Spread has a High Probability of Success

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

In April 2026, Biogen Inc. reported first-quarter 2026 results showing revenue of US$2.48 billion and net income of US$319.5 million, with earnings per share rising versus the prior year but accompanied by lower full-year guidance due to higher research and development spending and expected ...

Biogen stock reaction and recent performance snapshot Biogen (BIIB) has been in focus for investors after recent trading left the stock at a last close of $192.95. This has prompted fresh attention on how its current valuation lines up with underlying fundamentals.